Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.76 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.64 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.64 |
| ▸ | SCN1A | P35498 | 2/20 | 0.64 |
| ▸ | SCN4A | P35499 | 2/20 | 0.64 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.64 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.64 |
| ▸ | SCN2B | O60939 | 1/20 | 0.64 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.64 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL16759283 | 1.00 | SCN9A (0.76) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| SCHEMBL18662271 | 0.95 | SCN9A (0.82) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| SCHEMBL16770748 | 0.95 | SCN9A (0.82) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| Trifluoroacetic Acid SCHEMBL16758853 | 0.93 | SCN9A (0.77) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| Trifluoroacetic Acid SCHEMBL16758847 | 0.93 | SCN9A (0.77) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| Trifluoroacetic Acid SCHEMBL16758845 | 0.93 | SCN9A (0.77) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| Trifluoroacetic Acid SCHEMBL16759014 | 0.92 | SCN9A (0.75) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| Trifluoroacetic Acid SCHEMBL28880212 | 0.92 | SCN9A (0.75) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| SCHEMBL21825475 | 0.89 | SCN9A (0.85) | SCN9ASCN5ASCN7ASCN1ASCN4A | |
| SCHEMBL16770910 | 0.88 | SCN9A (0.84) | SCN9ASCN5ASCN7ASCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-105793238-B | Substituted benzamides and methods of use thereof | 基因泰克公司 | 2019-12-24 | — | — | CN | disclosed |
| EP-3074377-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1605/4885SCN5A 628/4885SCN7A 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.